Phospholipase D3 Variants Double Sporadic AD Risk
Exome sequencing identifies a new Alzheimer’s risk gene—phospholipase D3.
ALL NEWS
323 RESULTS
Sort By:
- Most Recent
- Most Commented
Biomarker Panel Predicts Slow or Fast ALS Course
A small panel of fluid biomarkers could predict a slow or fast disease course in amyotrophic lateral sclerosis.
Human Neurons Resist Effects of First-Generation γ-Secretase Modulators
First-generation γ-secretase modulators are less potent in human neurons than in some other cell types, possibly explaining why these drugs failed in clinical trials.
Merck BACE Inhibitor Clears a Safety Hurdle, Gets New Trial
Merck’s BACE inhibitor has survived its most recent safety evaluation and will undergo more testing in two trials—one for mild to moderate Alzheimer's, the other for mild cognitive impairment due to AD.
Premature Aging Protein Speeds Disease in Patient-Derived Neurons
The protein that causes progeria, the accelerated aging disease, hastens pathology in neurons derived from people with Parkinson's.
Risk Genes Influence Brain Connectivity in Preclinical FTD
A new study proposes that two genetic risk factors for frontotemporal dementia interact, disrupting brain connectivity decades before symptoms.
Stress Relief: Anti-Stress Granule Therapy Saves ALS Models
New research suggests that TDP-43 attacks neurons by deactivating a translation initiation factor. Keeping the factor active holds toxicity at bay in flies.
Meeting Explores Complex Biology of BACE Regulation
Researchers at BACE meeting explore how trafficking and degradation of the protease relate to amyloid pathology in AD.
Artificial Chaperone Keeps Amyloid-Forming Protein in Check
By stopping familial amyloid polyneuropathy in its tracks, a repurposed anti-inflammatory medication supports the idea that artificial chaperones can prevent protein aggregation.
International Winter Conference on Alzheimer's Disease 2012
Zuers—Meeting Mixes Translational News and Debate Zuers—Αlpha, Beta, Sigma: Which Will Yield New AD Drug? Zuers—No Pill or Drip: Scientists Inject Phage Drug Into CSF Zuers—Can Spatial Navigation Guide Clinical Trials? The town of Zuers in the Austrian Al
Gladstone Workshop: From Science to Therapeutics: The Best Way Forward
Therapeutic Approaches Target Deubiquitinase, Protein Turnover Paracrine Signal From BACE1-Clipped Neuregulin Rescues Myelin Could Longevity Factor, Epilepsy Med, Treat AD One Day? The small scientific workshop From Science to Therapeutics: The Best Way
American Academy of Neurology: 2013 Annual Meeting
Quick-and-Early IVIG Therapy: Hints of Promise? Anti-Amyloid Results Show Modest Benefits, Mild Side Effects Wrapping Up Enrollment, ADNI 2, PPMI Focus on Earlier Disease Drug Data Dash at AAN Annual Conference The ANN conference in San Diego covered such
Keystone Symposium: New Frontiers in Neurodegenerative Disease Research
Exploring Genome Fragmentation in Neurodegeneration Up-and-Coming ALS Mice Leave Scientists ConFUSed Does ALS Gene Police RNA, Keep Strands From Entangling? Does New Amyloid Protein Lend Tau a Hand? Keystone Symposium: New Frontiers in Neurodegenerative D
Venusberg Meeting on Neuroinflammation, 2013
Microglia Activation—Venusberg Meeting Questions M1, M2 Designations Inflammatory Crosstalk Between Periphery and Brain Blessing or Curse? Peripheral Cytokines in the Brain Glial Imaging—Amid Slow Progress, EU Project Takes Up Challenge Venusberg Meeting
ACT-AD FDA/AD Allies Meeting, 2012
Combination Drug Trials: Time to Open a New Front in AD? Combination Trials: FDA Puts Flesh on Bones of Draft Guidance Combination Trials: Companies Can Play Well in One Sandbox Building a Roadmap for Shared Combination Drug Trials ACT-AD FDA/AD Allies Me
Current Filters
- Date Range : Dec 2012 to Dec 2013 x